Depression Drugs - Global Market Outlook (2019 -2027)

According to Stratistics MRC, the Global Depression Drugs Market is accounted for $12.38 billion in 2019 and is expected to reach $16.68 billion by 2027 growing at a CAGR of 3.8% during the forecast period. Some of the factors such as growing healthcare expenditure and increasing insurance coverage are anticipated to fuel the market growth. However, side effects associated with these drugs along with the availability of other treatment methods such as psychotherapy is hindering the market growth.

Depression drugs are medications used to treat major depressive disorders, some anxiety disorders, chronic pain conditions, and to help manage some addictions. Common side effects of depression drugs include dry mouth, weight gain, dizziness, headaches, and sexual dysfunction.

Based on the drug class, the serotonin and norepinephrine reuptake inhibitors (SNRIs) segment is likely to have a huge demand due to SNRIs help relieve depression symptoms, essentially sadness and irritability. These neurotransmitters are known to affect mood. Serotonin is also called a "feel-good" because it is accompanied by positive feelings of wellbeing. Norepinephrine is associated with alertness and energy. SNRIs help treat depression by maintaining the levels of these two neurotransmitters in the brain. They do this by discontinuing norepinephrine and serotonin from going back into the cells that released them.

By geography, North America is estimated to have a lucrative growth owing to high patient awareness levels regarding the availability of various drugs for depression, rising healthcare expenditure and the relatively larger number of R&D exercises on drug manufacturing and marketing, etc. these factors contribute for significant revenue generation from the region.

Some of the key players profiled in the Depression Drugs Market include Abbott, Allergan, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer, AstraZeneca, Bristol-Myers Squibb, Zhejiang NHU Company Ltd, and Sebela Pharmaceuticals.

Disease Types Covered:

• Generalized Anxiety Disorder
• Major Depressive Disorder
• Obsessive-Compulsive Disorders (OCD)
• Schizophrenia and Bipolar I Disorder
• Panic Disorder
• Other Disease Types

Drug Classes Covered:

• Atypical Antidepressants
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants (TCAs)
• Anticonvulsants
• Beta-Blockers
• Norepinephrine-dopamine Reuptake Inhibitor (NDRI)
• Benzodiazepines
• Tetracyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Central Nervous System (CNS) Stimulants

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Drug Types Covered:

• Branded Drugs
• Generic Drugs

Brands Covered:

• Zoloft
• Cymbalta
• Prozac
• Paxil
• Lexapro
• Prestiq
• Celexa

Applications Covered:

• Hospitals
• Prosthetic Clinics
• Rehabilitation Center
• Research Centres

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2018, 2019 2020, 2024, and 2027
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Depression Drugs Market, By Disease Type

• 5.1 Introduction
• 5.2 Generalized Anxiety Disorder
• 5.3 Major Depressive Disorder
• 5.4 Obsessive-Compulsive Disorders (OCD)
• 5.5 Schizophrenia and Bipolar I Disorder
• 5.6 Panic Disorder
• 5.7 Other Disease Types
  • 5.7.1 Elective Serotonin Reuptake Inhibitors (SSRIs)-Induced Disorder
  • 5.7.2 Attention Deficit Hyperactivity Disorder (ADHD)

6 Global Depression Drugs Market, By Drug Class

• 6.1 Introduction
• 6.2 Atypical Antidepressants
• 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
• 6.4 Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• 6.5 Tricyclic Antidepressants (TCAs)
• 6.6 Anticonvulsants
• 6.7 Beta-Blockers
• 6.8 Norepinephrine-dopamine Reuptake Inhibitor (NDRI)
• 6.9 Benzodiazepines
• 6.10 Tetracyclic Antidepressants
• 6.11 Monoamine Oxidase Inhibitors
• 6.12 Central Nervous System (CNS) Stimulants

7 Global Depression Drugs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Depression Drugs Market, By Drug Type

• 8.1 Introduction
• 8.2 Branded Drugs
• 8.3 Generic Drugs

9 Global Depression Drugs Market, By Brand

• 9.1 Introduction
• 9.2 Zoloft
• 9.3 Cymbalta
• 9.4 Prozac
• 9.5 Paxil
• 9.6 Lexapro
• 9.7 Prestiq
• 9.8 Celexa

10 Global Depression Drugs Market, By Application

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Prosthetic Clinics
• 10.4 Rehabilitation Center
• 10.5 Research Centres

11 Global Depression Drugs Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott, Pfizer
• 13.2 Allergan
• 13.3 Eli Lilly and Company
• 13.4 GlaxoSmithKline
• 13.5 Johnson & Johnson
• 13.6 Novartis AG
• 13.7 Otsuka Pharmaceutical Co., Ltd.,
• 13.8 Takeda Pharmaceutical Company Limited
• 13.9 Pfizer
• 13.10 AstraZeneca
• 13.11 Bristol-Myers Squibb
• 13.12 Zhejiang NHU Company Ltd
• 13.13 Sebela Pharmaceuticals

List of Tables

• Table 1 Global Depression Drugs Market Outlook, By Region (2018-2027) ($MN)
• Table 2 Global Depression Drugs Market Outlook, By Disease Type (2018-2027) ($MN)
• Table 3 Global Depression Drugs Market Outlook, By Generalized Anxiety Disorder (2018-2027) ($MN)
• Table 4 Global Depression Drugs Market Outlook, By Major Depressive Disorder (2018-2027) ($MN)
• Table 5 Global Depression Drugs Market Outlook, By Obsessive-Compulsive Disorders (OCD) (2018-2027) ($MN)
• Table 6 Global Depression Drugs Market Outlook, By Schizophrenia and Bipolar I Disorder (2018-2027) ($MN)
• Table 7 Global Depression Drugs Market Outlook, By Panic Disorder (2018-2027) ($MN)
• Table 8 Global Depression Drugs Market Outlook, By Other Disease Types (2018-2027) ($MN)
• Table 9 Global Depression Drugs Market Outlook, By Elective Serotonin Reuptake Inhibitors (SSRIs)-Induced Disorder (2018-2027) ($MN)
• Table 10 Global Depression Drugs Market Outlook, By Attention Deficit Hyperactivity Disorder (ADHD) (2018-2027) ($MN)
• Table 11 Global Depression Drugs Market Outlook, By Drug Class (2018-2027) ($MN)
• Table 12 Global Depression Drugs Market Outlook, By Atypical Antidepressants (2018-2027) ($MN)
• Table 13 Global Depression Drugs Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2018-2027) ($MN)
• Table 14 Global Depression Drugs Market Outlook, By Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) (2018-2027) ($MN)
• Table 15 Global Depression Drugs Market Outlook, By Tricyclic Antidepressants (TCAs) (2018-2027) ($MN)
• Table 16 Global Depression Drugs Market Outlook, By Anticonvulsants (2018-2027) ($MN)
• Table 17 Global Depression Drugs Market Outlook, By Beta-Blockers (2018-2027) ($MN)
• Table 18 Global Depression Drugs Market Outlook, By Norepinephrine-dopamine Reuptake Inhibitor (NDRI) (2018-2027) ($MN)
• Table 19 Global Depression Drugs Market Outlook, By Benzodiazepines (2018-2027) ($MN)
• Table 20 Global Depression Drugs Market Outlook, By Tetracyclic Antidepressants (2018-2027) ($MN)
• Table 21 Global Depression Drugs Market Outlook, By Monoamine Oxidase Inhibitors (2018-2027) ($MN)
• Table 22 Global Depression Drugs Market Outlook, By Central Nervous System (CNS) Stimulants (2018-2027) ($MN)
• Table 23 Global Depression Drugs Market Outlook, By Distribution Channel (2018-2027) ($MN)
• Table 24 Global Depression Drugs Market Outlook, By Hospital Pharmacies (2018-2027) ($MN)
• Table 25 Global Depression Drugs Market Outlook, By Online Pharmacies (2018-2027) ($MN)
• Table 26 Global Depression Drugs Market Outlook, By Retail Pharmacies (2018-2027) ($MN)
• Table 27 Global Depression Drugs Market Outlook, By Drug Type (2018-2027) ($MN)
• Table 28 Global Depression Drugs Market Outlook, By Branded Drugs (2018-2027) ($MN)
• Table 29 Global Depression Drugs Market Outlook, By Generic Drugs (2018-2027) ($MN)
• Table 30 Global Depression Drugs Market Outlook, By Zoloft (2018-2027) ($MN)
• Table 31 Global Depression Drugs Market Outlook, By Cymbalta (2018-2027) ($MN)
• Table 32 Global Depression Drugs Market Outlook, By Prozac (2018-2027) ($MN)
• Table 33 Global Depression Drugs Market Outlook, By Paxil (2018-2027) ($MN)
• Table 34 Global Depression Drugs Market Outlook, By Lexapro (2018-2027) ($MN)
• Table 35 Global Depression Drugs Market Outlook, By Prestiq (2018-2027) ($MN)
• Table 36 Global Depression Drugs Market Outlook, By Celexa (2018-2027) ($MN)
• Table 37 Global Depression Drugs Market Outlook, By Application (2018-2027) ($MN)
• Table 38 Global Depression Drugs Market Outlook, By Hospitals (2018-2027) ($MN)
• Table 39 Global Depression Drugs Market Outlook, By Prosthetic Clinics (2018-2027) ($MN)
• Table 40 Global Depression Drugs Market Outlook, By Rehabilitation Center (2018-2027) ($MN)
• Table 41 Global Depression Drugs Market Outlook, By Research Centres (2018-2027) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.